Form 4: Ocular Therapeutix CEO Reports Stock Transactions

CEO Pravin Dugel reports a sell-to-cover tax transaction and a transfer of shares to an irrevocable trust.

Summary

• Pravin Dugel, Executive Chairman, President and CEO of Ocular Therapeutix, Inc., executed a sell-to-cover transaction of 21,156 shares on May 26, 2026, to satisfy tax obligations.
• The shares were sold at a weighted average price of $8.20 per share.
• On May 28, 2026, 394,696 shares were transferred from the reporting person's spouse to the Pravin Dugel 2024 Irrevocable Trust.
• The reporting person remains the beneficial owner of the shares held by the trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions are routine administrative actions related to tax obligations and estate planning.

Positives

• The sale of 21,156 shares was a non-discretionary transaction conducted under a pre-existing Rule 10b5-1 plan to cover tax liabilities.
• The transfer of shares to an irrevocable trust indicates long-term estate planning rather than a divestment of interest.

Negatives

• The filing reflects a reduction in direct holdings, though this is offset by the nature of the tax-related sell-to-cover mechanism.

Risks

• Reliance on Rule 10b5-1 plans for tax obligations is standard, but market volatility during the execution window can impact the realized price.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Management Comments

• The sales do not represent a discretionary trade by the reporting person.

Industry Context

StockSavvy.ai notes that sell-to-cover transactions are standard practice for executives in the biotech sector to manage tax liabilities associated with RSU vesting and generally do not signal a change in management sentiment regarding company performance.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans for tax-related sales is consistent with standard corporate governance practices for C-suite executives at publicly traded pharmaceutical companies.

Related Party Transactions

• Transfer of 394,696 shares to the Pravin Dugel 2024 Irrevocable Trust, of which the reporting person is the trustee and sole beneficiary.

Stakeholder Impact

• Minimal impact on shareholders as the transactions were non-discretionary or internal transfers.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

OCUL, Ocular Therapeutix, Insider Trading, Form 4, Pravin Dugel, Biotech